Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | -16.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16% |
| Mar 31, 2026 | 28.72% |
| Dec 31, 2025 | 41.90% |
| Sep 30, 2025 | 26.59% |
| Jun 30, 2025 | 58.09% |
| Mar 31, 2025 | 35.09% |
| Dec 31, 2024 | 53.48% |
| Sep 30, 2024 | 15.42% |
| Jun 30, 2024 | 18.30% |
| Mar 31, 2024 | -1.02% |
| Dec 31, 2023 | 15.07% |
| Sep 30, 2023 | 8.67% |